Literature DB >> 11719316

Histopathologic variability in usual and nonspecific interstitial pneumonias.

K R Flaherty1, W D Travis, T V Colby, G B Toews, E A Kazerooni, B H Gross, A Jain, R L Strawderman, A Flint, J P Lynch, F J Martinez.   

Abstract

Findings of surgical lung biopsy (SLB) are important in categorizing patients with idiopathic interstitial pneumonia (IIP). We investigated whether histologic variability would be evident in SLB specimens from multiple lobes in patients with IIP. SLBs from 168 patients, 109 of whom had multiple lobes biopsied, were reviewed by three pathologists. A diagnosis was assigned to each lobe. A different diagnosis was found between lobes in 26% of the patients. Patients with usual interstitial pneumonia (UIP) in all lobes were categorized as concordant for UIP (n = 51) and those with UIP in at least one lobe were categorized as discordant for UIP (n = 28). Patients with nonspecific interstitial pneumonia (NSIP) in all lobes were categorized as having fibrotic (n = 25) or cellular NSIP (n = 5). No consistent distribution of lobar histology was noted. Patients concordant for UIP were older (63 +/- 9 [mean +/- SD] yr; p < 0.05 as compared with all other groups) than those discordant for UIP (57 +/- 12 yr) or with fibrotic NSIP (56 +/- 11 yr) or cellular NSIP (50 +/- 9 yr). Semiquantitative high-resolution computed tomography demonstrated a varied profusion of fibrosis (p < 0.05 for all group comparisons), with more fibrosis in concordant UIP (2.13 +/- 0.62) than in discordant UIP (1.42 +/- 0.73), fibrotic NSIP (0.83 +/- 0.58), or cellular NSIP (0.44 +/- 0.42). Survival was better for patients with NSIP than for those in both UIP groups (p < 0.001), although survival in the two UIP groups was comparable (p = 0.16). Lobar histologic variability is frequent in patients with IIP, patients with a histologic pattern of UIP in any lobe should be classified as having UIP.

Entities:  

Mesh:

Year:  2001        PMID: 11719316     DOI: 10.1164/ajrccm.164.9.2103074

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  121 in total

1.  [Pulmonary fibrosis. Classification, diagnosis, therapy].

Authors:  U Costabel; J Guzman
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

Review 2.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

4.  Non-specific interstitial pneumonia; as the first clinical presentation of various collagen vascular disorders.

Authors:  Toshio Sato; Jiro Fujita; Ichiro Yamadori; Yuji Ohtsuki; Takeo Yoshinouchi; Shuji Bandoh; Michiaki Tokuda; Toshihiko Ishida
Journal:  Rheumatol Int       Date:  2005-11-08       Impact factor: 2.631

5.  Clinical and pathologic features of familial interstitial pneumonia.

Authors:  Mark P Steele; Marcy C Speer; James E Loyd; Kevin K Brown; Aretha Herron; Susan H Slifer; Lauranell H Burch; Momen M Wahidi; John A Phillips; Thomas A Sporn; H Page McAdams; Marvin I Schwarz; David A Schwartz
Journal:  Am J Respir Crit Care Med       Date:  2005-08-18       Impact factor: 21.405

Review 6.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

7.  VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis.

Authors:  Marianna Agassandian; John R Tedrow; John Sembrat; Daniel J Kass; Yingze Zhang; Elena A Goncharova; Naftali Kaminski; Rama K Mallampalli; Louis J Vuga
Journal:  Cell Signal       Date:  2015-09-18       Impact factor: 4.315

8.  Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis.

Authors:  Corrine R Kliment; Judson M Englert; Bernadette R Gochuico; Guoying Yu; Naftali Kaminski; Ivan Rosas; Tim D Oury
Journal:  J Biol Chem       Date:  2008-12-09       Impact factor: 5.157

9.  Treating CTDs related fibrotic ILDs by immunosuppressants: "facts and faults".

Authors:  Spyros A Papiris; Konstantinos Kagouridis; Georgia Papadaki; Likurgos Kolilekas; Effrosyni D Manali
Journal:  Lung       Date:  2013-11-12       Impact factor: 2.584

10.  Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis.

Authors:  Charlene D Fell; Fernando J Martinez; Lyrica X Liu; Susan Murray; Meilan K Han; Ella A Kazerooni; Barry H Gross; Jeffrey Myers; William D Travis; Thomas V Colby; Galen B Toews; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2010-01-07       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.